{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:30:02Z","timestamp":1780626602067,"version":"3.54.1"},"reference-count":9,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,10,24]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Drug-induced nephrolithiasis is an important consideration in recurrent stone formers with polypharmacy. While felbamate nephrolithiasis has previously been published in the paediatric population, we present the oldest published case of a felbamate stone in an adult, a man in his 30s with Lennox-Gastaut syndrome. Even with moderate dosing, high drug serum levels can occur. Performing at least one stone analysis remains a critical component to care in these patients. Urologists should have a high index of suspicion for drug stone when stone analysis returns indeterminate characterisation in the absence of infection. Close communication with neurology is key to preventing recurrent stone disease.<\/jats:p>","DOI":"10.1136\/bcr-2022-253883","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T12:35:30Z","timestamp":1703162130000},"page":"e253883","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Felbamate urolithiasis"],"prefix":"10.1136","volume":"16","author":[{"given":"Ilana","family":"Bergelson","sequence":"first","affiliation":[{"name":"Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, lowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chance","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah Health, Salt Lake City, Utah, USA"},{"name":"ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L","family":"Frank","sequence":"additional","affiliation":[{"name":"ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA"},{"name":"University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, lowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"2025082702025557000_16.12.e253883.1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40272-019-00355-5","article-title":"Drug-induced Urolithiasis in pediatric patients","volume":"21","author":"Sighinolfi","year":"2019","journal-title":"Paediatr Drugs"},{"key":"2025082702025557000_16.12.e253883.2","unstructured":"Hanrahan B , Carson RP . Felbamate. 2021. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539799"},{"key":"2025082702025557000_16.12.e253883.3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2018.10.016","article-title":"The pharmacological management of Lennox-Gastaut syndrome and critical literature review","volume":"63","author":"Verrotti","year":"2018","journal-title":"Seizure"},{"key":"2025082702025557000_16.12.e253883.4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"2025082702025557000_16.12.e253883.5","first-page":"227","article-title":"Drug-induced urinary calculi","volume":"5","author":"Matlaga","year":"2003","journal-title":"Rev Urol"},{"key":"2025082702025557000_16.12.e253883.6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1528-1157.2001.32500.x","article-title":"Felbamate Urolithiasis","volume":"42","author":"Sparagana","year":"2001","journal-title":"Epilepsia"},{"key":"2025082702025557000_16.12.e253883.7","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.juro.2012.12.032","article-title":"Urolithiasis in patients on high dose Felbamate","volume":"189","author":"Ghousheh","year":"2013","journal-title":"J Urol"},{"key":"2025082702025557000_16.12.e253883.8","unstructured":"Felbatol: package insert. Somerset, NJ. MEDA pharmaceuticals"},{"key":"2025082702025557000_16.12.e253883.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.05.006"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-253883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:03:02Z","timestamp":1756285382000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-253883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,21]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bcr-2022-253883"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-253883","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}